Abstract
We studied the effect of the severity of meningitis on the response to therapy with fluconazole and flucytosine in a murine model of cryptococcal meningitis. Meningitis was established by intracerebral injection of Cryptococcus neoformans. The severity of meningitis was varied by delaying the onset of treatment from 3 to 7 days. Animals were sacrificed after 14 days of treatment, and the numbers of C. neoformans per gram of brain tissue were quantified. The range of effective dose combinations of fluconazole and flucytosine became progressively reduced as the severity of meningitis increased. The magnitude of treatment effect, as measured by the numbers of CFU/gram of brain tissue, was also reduced with increasing severity of meningitis. In this model, as the severity of meningitis increases, higher doses of fluconazole are required to achieve equivalent levels of activity. The combination of fluconazole and flucytosine appears to have the most-potent antifungal effects. This is most readily observed in animals with more-severe meningitis.
Full Text
The Full Text of this article is available as a PDF (305.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Allendoerfer R., Marquis A. J., Rinaldi M. G., Graybill J. R. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1991 Apr;35(4):726–729. doi: 10.1128/aac.35.4.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
- Berry A. J., Rinaldi M. G., Graybill J. R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992 Mar;36(3):690–692. doi: 10.1128/aac.36.3.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larsen R. A., Bauer M., Weiner J. M., Diamond D. M., Leal M. E., Ding J. C., Rinaldi M. G., Graybill J. R. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1996 Sep;40(9):2178–2182. doi: 10.1128/aac.40.9.2178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larsen R. A., Bozzette S. A., Jones B. E., Haghighat D., Leal M. A., Forthal D., Bauer M., Tilles J. G., McCutchan J. A., Leedom J. M. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):741–745. doi: 10.1093/clinids/19.4.741. [DOI] [PubMed] [Google Scholar]
- Larsen R. A., Leal M. A., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med. 1990 Aug 1;113(3):183–187. doi: 10.7326/0003-4819-113-3-183. [DOI] [PubMed] [Google Scholar]
- Link C. L. Confidence intervals for the survival function using Cox's proportional-hazard model with covariates. Biometrics. 1984 Sep;40(3):601–609. [PubMed] [Google Scholar]
- Nguyen M. H., Barchiesi F., McGough D. A., Yu V. L., Rinaldi M. G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother. 1995 Aug;39(8):1691–1695. doi: 10.1128/aac.39.8.1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Grieco M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83–89. doi: 10.1056/NEJM199201093260202. [DOI] [PubMed] [Google Scholar]
- Shadomy S., Wagner G., Espinel-Ingroff E., Davis B. A. In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother. 1975 Aug;8(2):117–121. doi: 10.1128/aac.8.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]